Katy Moore

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

Kelong Han, Mark Baker, Mark Lovern et al. · British Journal of Clinical Pharmacology · 2022 · 54 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis

Chakradhar V. Lagishetty, Katy Moore, Peter Ackerman et al. · Clinical and Translational Science · 2020 · 21 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients

Katy Moore, A Savannah Mageau, Mindy Magee et al. · Open Forum Infectious Diseases · 2019 · 15 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants

Katy Moore, Nilay Thakkar, Mindy Magee et al. · Antimicrobial Agents and Chemotherapy · 2022 · 15 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir

Mindy Magee, Jill Slater, Frank Mannino et al. · The Journal of Clinical Pharmacology · 2020 · 13 citations

Pharmacy, Pharmacokinetics, Pharmacology +17